Sputum-based molecular biomarkers for the early detection of lung cancer: Limitations and promise

Cancers

Volumn 3, Issue 3, 2011, Pages 2975-2989

  Kim, Connie E ^a   Tchou Wong, Kam Meng ^a,b   Rom, William N ^a,b  

^a Division of Pulmonary Critical Care and Sleep Medicine   (United States)

^b NEW YORK UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Biomarker; Early detection; Lung cancer; Non small cell lung cancer; Sputum

Indexed keywords

BIOLOGICAL MARKER; DEATH ASSOCIATED PROTEIN KINASE; EPIDERMAL GROWTH FACTOR RECEPTOR; METHYLATED DNA PROTEIN CYSTEINE METHYLTRANSFERASE; MICRORNA; MICROSATELLITE DNA; RAS ASSOCIATION DOMAIN FAMILY PROTEIN 1A;

BRONCHUS MUCOSA; CANCER CYTODIAGNOSIS; CANCER MORPHOLOGY; CANCER SCREENING; DEATH ASSOCIATED PROTEIN KINASE GENE; DIAGNOSTIC VALUE; DNA METHYLATION; EARLY DIAGNOSIS; ENRICHMENT CULTURE; EPIDERMAL GROWTH FACTOR RECEPTOR GENE; GATA GENE; GENE EXPRESSION; GENE MUTATION; HETEROZYGOSITY LOSS; HUMAN; LUNG CANCER; LUNG NON SMALL CELL CANCER; LUNG SMALL CELL CANCER; MICROSATELLITE INSTABILITY; O6 METHYLGUANINE DNA METHYLTRANSFERASE GENE; ONCOGENE K RAS; PAX5 GENE; RAS ASSOCIATION DOMAIN FAMILY MEMBER 1A GENE; REPRODUCIBILITY; REVIEW; SPUTUM CYTODIAGNOSIS; THORAX RADIOGRAPHY; TP53 GENE; TUMOR SUPPRESSOR GENE;

EID: 80053217737     PISSN: None     EISSN: 20726694     Source Type: Journal    
DOI: 10.3390/cancers3032975     Document Type: Review

References (82)

1. Jemal, A.; Siegel, R.; Xu, J.; Ward, E. Cancer statistics, 2010. CA: Cancer J. Clin. 2010, 60, 277-300.
2. The National Lung Screening Trial Research Team. Reduced lung-cancer mortality with low-dose computed tomographic screening. New Engl. J. Med. 2011, doi: 10.1056/NEJMoa1102873.
3. Toloza, E.M.; Harpole, L.; McCrory, D.C. Noninvasive staging of non-small cell lung cancer: A review of the current evidence. Chest 2003, 123, 137S-146S.
4. Secretan, B.; Straif, K.; Baan, R.; Grosse, Y.; El Ghissassi, F.; Bouvard, V.; Benbrahim-Tallaa, L.; Guha, N.; Freeman, C.; Galichet, L. et al. A review of human carcinogens-part E: Tobacco, areca nut, alcohol, coal smoke, and salted fish. Lancet Oncol. 2009, 10, 1033-1034.
5. Siegfried, J.M. Biology and chemoprevention of lung cancer. Chest 1998, 113, 40S-45S.
6. Saccomanno, G.; Archer, V.E.; Auerbach, O.; Saunders, R.P.; Brennan, L.M. Development of carcinoma of the lung as reflected in exfoliated cells. Cancer 1974, 33, 256-270.
7. Hirsch, F.R.; Franklin, W.A.; Gazdar, A.F.; Bunn, P.A., Jr. Early detection of lung cancer: Clinical perspectives of recent advances in biology and radiology. Clin. Cancer Res. 2001, 7, 5-22.
8. Tockman, M.S.; Frost, J.K.; Stitik, F.P.; Levin, M.L.; Ball, W.C., Jr.; March, B.R. Screening and Detection of Lung Cancer. I; Churchill Livingstone: New York, NY, USA, 1985; pp. 25-40.
9. Melamed, M.R.; Flehinger, B.J.; Zaman, M.B.; Heelan, R.T.; Perchick, W.A.; Martini, N. Screening for early lung cancer. Results of the memorial sloan-kettering study in new york. Chest 1984, 86, 44-53.
10. Lam, B.; Lam, S.Y.; Wong, M.P.; Ooi, C.G.; Fong, D.Y.; Lam, D.C.; Lai, A.Y.; Tam, C.M.; Pang, C.B.; Ip, M.S. et al. Sputum cytology examination followed by autofluorescence bronchoscopy: A practical way of identifying early stage lung cancer in central airway. Lung Cancer 2009, 64, 289-294.
11. Varella-Garcia, M.; Schulte, A.P.; Wolf, H.J.; Feser, W.J.; Zeng, C.; Braudrick, S.; Yin, X.; Hirsch, F.R.; Kennedy, T.C.; Keith, R.L. et al. The detection of chromosomal aneusomy by fluorescence in situ hybridization in sputum predicts lung cancer incidence. Cancer Prev. Res. (Phila) 2010, 3, 447-453.
12. Xing, S.; Khanavkar, B.; Nakhosteen, J.A.; Atay, Z.; Jockel, K.H.; Marek, W. Predictive value of image cytometry for diagnosis of lung cancer in heavy smokers. Eur. Respir. J. 2005, 25, 956-963.
13. Kemp, R.A.; Reinders, D.M.; Turic, B. Detection of lung cancer by automated sputum cytometry. J. Thorac. Oncol. 2007, 2, 993-1000.
14. Jensen, S.A.; Vainer, B.; Kruhoffer, M.; Sorensen, J.B. Microsatellite instability in colorectal cancer and association with thymidylate synthase and dihydropyrimidine dehydrogenase expression. BMC Cancer 2009, 9, 25.
15. Fishel, R.; Lescoe, M.K.; Rao, M.R.; Copeland, N.G.; Jenkins, N.A.; Garber, J.; Kane, M.; Kolodner, R. The human mutator gene homolog msh2 and its association with hereditary nonpolyposis colon cancer. Cell 1993, 75, 1027-1038.
16. Aaltonen, L.A.; Peltomaki, P.; Leach, F.S.; Sistonen, P.; Pylkkanen, L.; Mecklin, J.P.; Jarvinen, H.; Powell, S.M.; Jen, J.; Hamilton, S.R. et al. Clues to the pathogenesis of familial colorectal cancer. Science 1993, 260, 812-816.
17. Berg, D.T.; Walls, J.D.; Reifel-Miller, A.E.; Grinnell, B.W. E1a-induced enhancer activity of the poly(dg-dt).Poly(da-dc) element (gt element) and interactions with a gt-specific nuclear factor. Mol. Cell Biol. 1989, 9, 5248-5253.
18. Hamada, H.; Seidman, M.; Howard, B.H.; Gorman, C.M. Enhanced gene expression by the poly(dt-dg). Poly(dc-da) sequence. Mol. Cell Biol. 1984, 4, 2622-2630.
19. Zheng, H.T.; Peng, Z.H.; Li, S.; He, L. Loss of heterozygosity analyzed by single nucleotide polymorphism array in cancer. World J. Gastroenterol. 2005, 11, 6740-6744.
20. Hoque, M.O.; Lee, C.C.; Cairns, P.; Schoenberg, M.; Sidransky, D. Genome-wide genetic characterization of bladder cancer: A comparison of high-density single-nucleotide polymorphism arrays and pcr-based microsatellite analysis. Cancer Res. 2003, 63, 2216-2222.
21. Mei, R.; Galipeau, P.C.; Prass, C.; Berno, A.; Ghandour, G.; Patil, N.; Wolff, R.K.; Chee, M.S.; Reid, B.J.; Lockhart, D.J. Genome-wide detection of allelic imbalance using human snps and high-density DNA arrays. Genome Res. 2000, 10, 1126-1137.
22. Castagnaro, A.; Marangio, E.; Verduri, A.; Chetta, A.; D'Ippolito, R.; Del Donno, M.; Olivieri, D.; Di Cola, G. Microsatellite analysis of induced sputum DNA in patients with lung cancer in heavy smokers and in healthy subjects. Exp. Lung Res. 2007, 33, 289-301.
23. Hsu, H.S.; Chen, T.P.; Wen, C.K.; Hung, C.H.; Chen, C.Y.; Chen, J.T.; Wang, Y.C. Multiple genetic and epigenetic biomarkers for lung cancer detection in cytologically negative sputum and a nested case-control study for risk assessment. J. Pathol. 2007, 213, 412-419.
24. Katz, R.L.; Zaidi, T.M.; Fernandez, R.L.; Zhang, J.; He, W.; Acosta, C.; Daniely, M.; Madi, L.; Vargas, M.A.; Dong, Q. et al. Automated detection of genetic abnormalities combined with cytology in sputum is a sensitive predictor of lung cancer. Mod. Pathol. 2008, 21, 950-960.
25. Carozzi, F.M.; Bisanzi, S.; Falini, P.; Sani, C.; Venturini, G.; Lopes Pegna, A.; Bianchi, R.; Ronchi, C.; Picozzi, G.; Mascalchi, M. et al. Molecular profile in body fluids in subjects enrolled in a randomised trial for lung cancer screening: Perspectives of integrated strategies for early diagnosis. Lung Cancer 2010, 68, 216-221.
26. Wang, Y.C.; Hsu, H.S.; Chen, T.P.; Chen, J.T. Molecular diagnostic markers for lung cancer in sputum and plasma. Ann. N Y Acad. Sci. 2006, 1075, 179-184.
27. Angeloni, D. Molecular analysis of deletions in human chromosome 3p21 and the role of resident cancer genes in disease. Brief Funct. Genomic Proteomic 2007, 6, 19-39.
28. Croce, C.M.; Sozzi, G.; Huebner, K. Role of fhit in human cancer. J. Clin. Oncol. 1999, 17, 1618-1624.
29. Nagayama, K.; Kohno, T.; Sato, M.; Arai, Y.; Minna, J.D.; Yokota, J. Homozygous deletion scanning of the lung cancer genome at a 100-kb resolution. Genes Chromosomes Cancer 2007, 46, 1000-1010.
30. Bird, A. DNA methylation patterns and epigenetic memory. Genes Dev. 2002, 16, 6-21.
31. Jones, P.A.; Baylin, S.B. The fundamental role of epigenetic events in cancer. Nat. Rev. Genet. 2002, 3, 415-428.
32. Tessema, M.; Belinsky, S.A. Mining the epigenome for methylated genes in lung cancer. Proc. Am. Thorac. Soc. 2008, 5, 806-810.
33. Belinsky, S.A. Gene-promoter hypermethylation as a biomarker in lung cancer. Nat. Rev. Cancer 2004, 4, 707-717.
34. Belinsky, S.A.; Palmisano, W.A.; Gilliland, F.D.; Crooks, L.A.; Divine, K.K.; Winters, S.A.; Grimes, M.J.; Harms, H.J.; Tellez, C.S.; Smith, T.M. et al. Aberrant promoter methylation in bronchial epithelium and sputum from current and former smokers. Cancer Res. 2002, 62, 2370-2377.
35. Foster, S.A.; Wong, D.J.; Barrett, M.T.; Galloway, D.A. Inactivation of p16 in human mammary epithelial cells by cpg island methylation. Mol. Cell Biol. 1998, 18, 1793-1801.
36. Pegg, A.E. Repair of o(6)-alkylguanine by alkyltransferases. Mutat. Res. 2000, 462, 83-100.
37. Donninger, H.; Vos, M.D.; Clark, G.J. The rassf1a tumor suppressor. J. Cell Sci. 2007, 120, 3163-3172.
38. Patra, S.K.; Szyf, M. DNA methylation-mediated nucleosome dynamics and oncogenic ras signaling: Insights from fas, fas ligand and rassf1a. FEBS J. 2008, 275, 5217-5235.
39. Raveh, T.; Droguett, G.; Horwitz, M.S.; DePinho, R.A.; Kimchi, A. Dap kinase activates a p19arf/p53-mediated apoptotic checkpoint to suppress oncogenic transformation. Nat. Cell Biol. 2001, 3, 1-7.
40. Belinsky, S.A.; Grimes, M.J.; Casas, E.; Stidley, C.A.; Franklin, W.A.; Bocklage, T.J.; Johnson, D.H.; Schiller, J.H. Predicting gene promoter methylation in non-small-cell lung cancer by evaluating sputum and serum. Br. J. Cancer 2007, 96, 1278-1283.
41. Belinsky, S.A.; Klinge, D.M.; Dekker, J.D.; Smith, M.W.; Bocklage, T.J.; Gilliland, F.D.; Crowell, R.E.; Karp, D.D.; Stidley, C.A.; Picchi, M.A. Gene promoter methylation in plasma and sputum increases with lung cancer risk. Clin. Cancer Res. 2005, 11, 6505-6511.
42. Liu, Y.; An, Q.; Li, L.; Zhang, D.; Huang, J.; Feng, X.; Cheng, S.; Gao, Y. Hypermethylation of p16ink4a in chinese lung cancer patients: Biological and clinical implications. Carcinogenesis 2003, 24, 1897-1901.
43. Shivapurkar, N.; Stastny, V.; Suzuki, M.; Wistuba, II; Li, L.; Zheng, Y.; Feng, Z.; Hol, B.; Prinsen, C.; Thunnissen, F.B. et al. Application of a methylation gene panel by quantitative pcr for lung cancers. Cancer Lett. 2007, 247, 56-71.
44. Belinsky, S.A.; Liechty, K.C.; Gentry, F.D.; Wolf, H.J.; Rogers, J.; Vu, K.; Haney, J.; Kennedy, T.C.; Hirsch, F.R.; Miller, Y. et al. Promoter hypermethylation of multiple genes in sputum precedes lung cancer incidence in a high-risk cohort. Cancer Res. 2006, 66, 3338-3344.
45. Honorio, S.; Agathanggelou, A.; Schuermann, M.; Pankow, W.; Viacava, P.; Maher, E.R.; Latif, F. Detection of rassf1a aberrant promoter hypermethylation in sputum from chronic smokers and ductal carcinoma in situ from breast cancer patients. Oncogene 2003, 22, 147-150.
46. Palmisano, W.A.; Divine, K.K.; Saccomanno, G.; Gilliland, F.D.; Baylin, S.B.; Herman, J.G.; Belinsky, S.A. Predicting lung cancer by detecting aberrant promoter methylation in sputum. Cancer Res. 2000, 60, 5954-5958.
47. Baryshnikova, E.; Destro, A.; Infante, M.V.; Cavuto, S.; Cariboni, U.; Alloisio, M.; Ceresoli, G.L.; Lutman, R.; Brambilla, G.; Chiesa, G. et al. Molecular alterations in spontaneous sputum of cancer-free heavy smokers: Results from a large screening program. Clin. Cancer Res. 2008, 14, 1913-1919.
48. Kersting, M.; Friedl, C.; Kraus, A.; Behn, M.; Pankow, W.; Schuermann, M. Differential frequencies of p16(ink4a) promoter hypermethylation, p53 mutation, and k-ras mutation in exfoliative material mark the development of lung cancer in symptomatic chronic smokers. J. Clin. Oncol. 2000, 18, 3221-3229.
49. Herman, J.G.; Graff, J.R.; Myohanen, S.; Nelkin, B.D.; Baylin, S.B. Methylation-specific pcr: A novel pcr assay for methylation status of cpg islands. Proc. Natl. Acad. Sci. USA 1996, 93, 9821-9826.
50. Gore, S.D.; Baylin, S.; Sugar, E.; Carraway, H.; Miller, C.B.; Carducci, M.; Grever, M.; Galm, O.; Dauses, T.; Karp, J.E. et al. Combined DNA methyltransferase and histone deacetylase inhibition in the treatment of myeloid neoplasms. Cancer Res. 2006, 66, 6361-6369.
51. Zochbauer-Muller, S.; Gazdar, A.F.; Minna, J.D. Molecular pathogenesis of lung cancer. Annu. Rev. Physiol. 2002, 64, 681-708.
52. Carson, D.A.; Lois, A. Cancer progression and p53. Lancet 1995, 346, 1009-1011.
53. Hollstein, M.; Sidransky, D.; Vogelstein, B.; Harris, C.C. P53 mutations in human cancers. Science 1991, 253, 49-53.
54. Ding, L.; Getz, G.; Wheeler, D.A.; Mardis, E.R.; McLellan, M.D.; Cibulskis, K.; Sougnez, C.; Greulich, H.; Muzny, D.M.; Morgan, M.B. et al. Somatic mutations affect key pathways in lung adenocarcinoma. Nature 2008, 455, 1069-1075.
55. Whibley, C.; Pharoah, P.D.; Hollstein, M. P53 polymorphisms: Cancer implications. Nat. Rev. Cancer 2009, 9, 95-107.
56. Olivier, M.; Hollstein, M.; Hainaut, P. Tp53 mutations in human cancers: Origins, consequences, and clinical use. Cold Spring Harb. Perspect. Biol. 2010, 2, a001008.
57. Riely, G.J.; Marks, J.; Pao, W. Kras mutations in non-small cell lung cancer. Proc. Am. Thorac. Soc. 2009, 6, 201-205.
58. Bos, J.L. Ras oncogenes in human cancer: A review. Cancer Res. 1989, 49, 4682-4689.
59. Pao, W.; Chmielecki, J. Rational, biologically based treatment of egfr-mutant non-small-cell lung cancer. Nat. Rev. Cancer 2010, 10, 760-774.
60. Hynes, N.E.; Lane, H.A. Erbb receptors and cancer: The complexity of targeted inhibitors. Nat. Rev. Cancer 2005, 5, 341-354.
61. Jimeno, A.; Hidalgo, M. Pharmacogenomics of epidermal growth factor receptor (egfr) tyrosine kinase inhibitors. Biochim. Biophys. Acta 2006, 1766, 217-229.
62. Lynch, T.J.; Bell, D.W.; Sordella, R.; Gurubhagavatula, S.; Okimoto, R.A.; Brannigan, B.W.; Harris, P.L.; Haserlat, S.M.; Supko, J.G.; Haluska, F.G. et al. Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib. N. Engl. J. Med. 2004, 350, 2129-2139.
63. Paez, J.G.; Janne, P.A.; Lee, J.C.; Tracy, S.; Greulich, H.; Gabriel, S.; Herman, P.; Kaye, F.J.; Lindeman, N.; Boggon, T.J. et al. Egfr mutations in lung cancer: Correlation with clinical response to gefitinib therapy. Science 2004, 304, 1497-1500.
64. da Cunha Santos, G.; Shepherd, F.A.; Tsao, M.S. Egfr mutations and lung cancer. Annu. Rev. Pathol. 2011, 6, 49-69.
65. Zhang, L.F.; Gao, W.M.; Gealy, R.; Weissfeld, J.; Elder, E.; Whiteside, T.L.; Keohavong, P. Comparison of k-ras gene mutations in tumour and sputum DNA of patients with lung cancer. Biomarkers 2003, 8, 156-161.
66. Wang, B.; Li, L.; Yao, L.; Liu, L.; Zhu, Y. Detection of p53 gene mutations in sputum samples and their implications in the early diagnosis of lung cancer in suspicious patients. Chin. Med. J. (Engl.) 2001, 114, 694-697.
67. Choi, Y.L.; Soda, M.; Yamashita, Y.; Ueno, T.; Takashima, J.; Nakajima, T.; Yatabe, Y.; Takeuchi, K.; Hamada, T.; Haruta, H. et al. Eml4-alk mutations in lung cancer that confer resistance to alk inhibitors. N. Engl. J. Med. 2010, 363, 1734-1739.
68. Kan, Z.; Jaiswal, B.S.; Stinson, J.; Janakiraman, V.; Bhatt, D.; Stern, H.M.; Yue, P.; Haverty, P.M.; Bourgon, R.; Zheng, J. et al. Diverse somatic mutation patterns and pathway alterations in human cancers. Nature 2010, 466, 869-873.
69. Bartel, D.P. Micrornas: Genomics, biogenesis, mechanism, and function. Cell 2004, 116, 281-297.
70. Esquela-Kerscher, A.; Slack, F.J. Oncomirs - micrornas with a role in cancer. Nat. Rev. Cancer 2006, 6, 259-269.
71. Yanaihara, N.; Caplen, N.; Bowman, E.; Seike, M.; Kumamoto, K.; Yi, M.; Stephens, R.M.; Okamoto, A.; Yokota, J.; Tanaka, T. et al. Unique microrna molecular profiles in lung cancer diagnosis and prognosis. Cancer Cell 2006, 9, 189-198.
72. Volinia, S.; Calin, G.A.; Liu, C.G.; Ambs, S.; Cimmino, A.; Petrocca, F.; Visone, R.; Iorio, M.; Roldo, C.; Ferracin, M. et al. A microrna expression signature of human solid tumors defines cancer gene targets. Proc. Natl. Acad. Sci. USA 2006, 103, 2257-2261.
73. Xing, L.; Todd, N.W.; Yu, L.; Fang, H.; Jiang, F. Early detection of squamous cell lung cancer in sputum by a panel of microrna markers. Mod. Pathol. 2010, 8, 1157-1164.
74. Yu, L.; Todd, N.W.; Xing, L.; Xie, Y.; Zhang, H.; Liu, Z.; Fang, H.; Zhang, J.; Katz, R.L.; Jiang, F. Early detection of lung adenocarcinoma in sputum by a panel of microrna markers. Int. J. Cancer 2010, 127, 2870-2878.
75. Xing, L.; Todd, N.W.; Yu, L.; Fang, H.; Jiang, F. Early detection of squamous cell lung cancer in sputum by a panel of microrna markers. Mod. Pathol. 2010, 23, 1157-1164.
76. Xie, Y.; Todd, N.W.; Liu, Z.; Zhan, M.; Fang, H.; Peng, H.; Alattar, M.; Deepak, J.; Stass, S.A.; Jiang, F. Altered mirna expression in sputum for diagnosis of non-small cell lung cancer. Lung Cancer 2010, 67, 170-176.
77. Belda, J.; Leigh, R.; Parameswaran, K.; O'Byrne, P.M.; Sears, M.R.; Hargreave, F.E. Induced sputum cell counts in healthy adults. Am. J. Respir. Crit. Care Med. 2000, 161, 475-478.
78. Fahy, J.V.; Boushey, H.A.; Lazarus, S.C.; Mauger, E.A.; Cherniack, R.M.; Chinchilli, V.M.; Craig, T.J.; Drazen, J.M.; Ford, J.G.; Fish, J.E. et al. Safety and reproducibility of sputum induction in asthmatic subjects in a multicenter study. Am. J. Respir. Crit. Care. Med. 2001, 163, 1470-1475.
79. Keohavong, P.; Gao, W.M.; Zheng, K.C.; Mady, H.; Lan, Q.; Melhem, M.; Mumford, J. Detection of k-ras and p53 mutations in sputum samples of lung cancer patients using laser capture microdissection microscope and mutation analysis. Anal. Biochem. 2004, 324, 92-99.
80. Keohavong, P.; Lan, Q.; Gao, W.M.; Zheng, K.C.; Mady, H.H.; Melhem, M.F.; Mumford, J.L. Detection of p53 and k-ras mutations in sputum of individuals exposed to smoky coal emissions in xuan wei county, china. Carcinogenesis 2005, 26, 303-308.
81. Qiu, Q.; Todd, N.W.; Li, R.; Peng, H.; Liu, Z.; Yfantis, H.G.; Katz, R.L.; Stass, S.A.; Jiang, F. Magnetic enrichment of bronchial epithelial cells from sputum for lung cancer diagnosis. Cancer 2008, 114, 275-283.
82. Roy, H.K.; Subramanian, H.; Damania, D.; Hensing, T.A.; Rom, W.N.; Pass, H.I.; Ray, D.; Rogers, J.D.; Bogojevic, A.; Shah, M. et al. Optical detection of buccal epithelial nanoarchitectural alterations in patients harboring lung cancer: Implications for screening. Cancer Res. 2010, 70, 7748-7754.